시장보고서

상품코드

1780305

백신 시장 규모와 예측(2021-2031년) : 세계 및 지역 점유율, 동향, 성장 기회 분석 리포트 - 유형, 질환 적응증, 투여 경로, 연령층, 지역

Vaccines Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: Type, Indication, Route of Administration, Age Group, and Geography

발행일: 2025년 07월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 226 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

>백신 시장 규모는 2024년 804억 5,000만 달러에서 2031년에는 1,189억 4,000만 달러로 성장할 것으로 예측되고 있으며, 2025-2031년 CAGR은 5.7%로 예측됩니다. 감염병 및 질병 발생 증가, 예방접종 프로그램의 급증 및 정부의 구상은 백신 시장 규모 확대에 기여하고 있는 주목할 만한 요인입니다. 그러나 백신 개발 비용이 높고, 시장 개발에 시간이 오래 걸린다는 점이 백신 시장 성장의 걸림돌로 작용하고 있습니다.

인공지능(AI)과 머신러닝은 속도와 정확성을 높이는 혁신적인 방법을 도입하여 백신 연구개발의 전망을 재구성하고 있습니다. AI의 가장 중요한 용도 중 하나는 복잡한 유전체-면역 데이터 분석입니다. 이 기술을 통해 기존에는 몇 년이 걸리던 방대한 데이터를 선별하여 잠재적인 백신 타겟을 빠르게 찾아낼 수 있게 되었습니다. 이러한 표적에 대한 면역 반응을 예측할 수 있는 능력은 특히 획기적이며, 더 짧은 시간 내에 백신을 설계할 수 있는 인사이트를 제공합니다.

AI의 전략적 가치는 COVID-19 팬데믹 상황에서 mRNA 백신 개발의 임상시험 일정을 앞당기는 데 중요한 역할을 했으며, 기업은 바이러스 유전체 시퀀싱에서 규제 당국의 승인까지 1년 이내에 완료할 수 있었습니다. 2021년 화이자는 첨단 AI 기반 플랫폼 SDQ를 활용하여 임상 데이터 처리를 간소화했습니다. 이 머신러닝 툴은 임상시험 데이터 정리 및 분석에 소요되는 시간을 유효성 마일스톤 달성 후 30일 이상 걸리던 것을 22시간으로 단축시켜 업무 효율성과 시장 출시 속도를 크게 향상시켰습니다.

제조 분야에서는 AI의 도입으로 생산 효율성이 크게 향상됩니다. AI 시스템은 제조 공정의 여러 단계를 간소화하고, 예상 표준에서 벗어난 부분을 모니터링 및 식별하여 품질관리를 강화하며, 백신 공급을 지연시킬 수 있는 잠재적 병목 현상을 예측할 수 있습니다. 이러한 사전 예방적 접근 방식은 생산 일정을 앞당길 뿐만 아니라 백신을 보다 안정적으로 생산할 수 있도록 보장합니다. 2025년 3월, 로스알라모스는 로스알라모스 국립연구소의 과학자들이 백신과 의약품 개발을 가속화하기 위해 실험 데이터와 AI를 결합하고 있다고 발표했습니다. RAPTER 백신 개발 프로젝트는 AI와 실험적 연구를 활용하여 기존의 연구 방법을 가속화합니다. 이 프로젝트는 병원체의 유전자 염기서열을 분석하여 신속한 발병 대응을 위한 효과적인 백신 옵션을 식별하는 예측 툴을 만드는 것을 목표로 하고 있습니다. 연구팀은 AI 기반 지식 추출, 메커니즘 모델링, 유망 후보를 테스트하기 위한 in vitro 및 in vivo 실험을 통해 이 툴을 개발하고 있습니다. RAPTER는 우선 세 가지 병원균에 초점을 맞출 예정입니다. SARS-CoV-2, 에볼라 바이러스, 그리고 심각한 생물학적 위협으로 간주되는 메리오이드증 원인균인 버크홀데리아 슈도말레입니다.

전반적으로 AI와 머신러닝을 백신 개발 프로세스에 통합함으로써 이 중요한 분야를 보다 효율적이고 확장 가능하며, 빠르게 진화하는 세계 건강 위협 상황에 적응할 수 있도록 하고, 궁극적으로 보다 효과적인 공중보건 대응에 기여하고 있습니다. 이는 향후 수년간 백신 시장의 성장에 기여할 것으로 예측됩니다.

연령대별 인사이트

연령대에 따라 백신 시장은 소아용과 성인용으로 구분됩니다. 2024년 백신 시장 점유율은 소아용이 가장 클 것으로 예측됩니다. 소아용 백신은 영유아기나 소아기에 심각한 위험을 초래하는 감염성 질환으로부터 자신을 보호하기 위해 접종하는 예방접종입니다. 이러한 백신은 일반적으로 국가 예방접종 프로그램에 포함되어 있으며, 디프테리아, 백일해, 파상풍(DTP), 소아마비, 로타바이러스, 홍역, 유행성이하선염, 풍진(MMR), B형 간염, 폐렴구균 등의 질병에 대한 예방이 포함되어 있습니다. 이 분야는 유아기 면역에 대한 인식 증가, 단체의 세계 보급 활동 증가, 선진국과 개발도상국 모두에서 정부의 강력한 의무화로 인해 지속적으로 성장하고 있습니다. 백신으로 예방할 수 있는 영유아의 질병 부담과 조기 예방접종의 장기적인 건강 및 경제적 이익은 지속적인 정책 및 재정적 지원으로 이어지고 있습니다. 주사 횟수를 줄이는 혼합백신(5가, 6가 등)과 소아 HPV 백신, 말라리아 백신과 같은 새로운 백신이 추가되면서 소아 백신 포트폴리오가 더욱 확대되고 있습니다. 또한 내열성, 무침 전달 시스템 등 백신 기술의 발전도 저자원 지역 지원 활동을 지원하며 백신 시장의 성장에 박차를 가하고 있습니다.

세계보건기구(WHO) 및 유니세프(UNICEF)는 백신 시장 보고서 작성시 참고한 1차 및 2차 정보 중 하나입니다.

백신 시장 - 주요 시장 역학
시장 성장 촉진요인
- 감염증 및 질병 발생의 증가
- 예방 접종 프로그램의 급증과 정부 구상
시장 성장 억제요인
- 높은 백신 개발비와 시장 개발 기간의 장기화
시장 기회
- 혼합 백신 및 치료용 백신의 개발
향후 동향
- 백신 개발에서 인공지능과 빅데이터의 통합
촉진요인과 억제요인의 영향

제6장 백신 시장 : 세계 시장 분석

백신 - 세계 시장 개요
백신 - 세계 시장과 2031년까지의 예측

제7장 백신 시장 - 매출 분석 : 기술별, 2020-2031년

생백신
불활화 백신과 서브유닛 백신
톡소이드 백신
결합형 백신
재조합 백신
기타

제8장 백신 시장 - 매출 분석 : 질환 적응증별, 2020-2031년

인플루엔자
뎅기열
거대세포바이러스(CMV)
간염
호흡기 증후군 바이러스(RSV)
기타 질환

제9장 백신 시장 - 매출 분석 : 투여 경로별, 2020-2031년

경구
주사제
기타 투여 경로

제10장 백신 시장 - 매출 분석 : 환자 유형별, 2020-2031년

소아
성인

제11장 백신 시장 - 매출 분석 : 지역별 분석, 2020-2031년

북미
- 미국
- 캐나다
- 멕시코
유럽
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- 아시아태평양의 기타 국가
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 기타 중동 및 아프리카
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제12장 업계 상황

합병과 인수
계약, 제휴, 합병사업
신제품 출시
사업 확대와 기타 전략적 개발

제13장 경쟁 구도

주요 기업에 의한 히트맵 분석
주요 기업별 순위

제14장 백신 시장 - 주요 기업 개요

GlaxoSmithKline plc
Pfizer Inc.
Sanofi
Merck and Co., Inc
Serum Institute of India(SII)
BioNTech
Abbott
Sinovac
Novartis
CSL Seqirus

제15장 주요 기업 개요 부록

KSA 25.08.07

The vaccines market size is expected to grow from US$ 80.45 billion in 2024 to US$ 118.94 billion by 2031; it is projected to register a CAGR of 5.7% during 2025-2031. The growing incidences of infectious diseases and disease outbreaks, and surging immunization programs and government initiatives are noteworthy factors contributing to the expansion of the vaccines market size. However, the high vaccine development cost and increased time to market hinder the vaccines market growth.

Artificial intelligence (AI) and machine learning are reshaping the landscape of vaccine research and development by introducing innovative methodologies that enhance speed and accuracy. One of the most critical applications of AI is in the analysis of complex genomic and immunological data. This technology enables researchers to rapidly identify potential vaccine targets by sifting through vast amounts of data-a process that would have traditionally taken years to accomplish. The ability to predict immune responses to these targets is particularly revolutionary, providing insights to design vaccines in a much shorter timeframe.

The strategic value of AI was evident during the COVID-19 pandemic, where it played a critical role in accelerating mRNA vaccine development clinical trials timelines, enabling companies to move from viral genome sequencing to regulatory approval within a year. In 2021, Pfizer leveraged an advanced AI-driven platform, SDQ, to streamline clinical data processing. This machine learning tool reduced the time required to clean and analyze trial data from over 30 days to just 22 hours after reaching efficacy milestones, significantly enhancing operational efficiency and speed to market.

In the manufacturing arena, the implementation of AI significantly enhances production efficiency. AI systems can streamline various stages of the production process, enhance quality control by monitoring and identifying deviations from expected standards, and forecast potential bottlenecks that could delay vaccine delivery. This proactive approach not only speeds up the production timeline but also ensures that vaccines are manufactured with a higher degree of reliability. In March 2025, Los Alamos announced that the scientists in Los Alamos National Laboratory are combining experimental data and AI for accelerating vaccine and drug development. The RAPTER vaccine development project is leveraging AI and experimental studies to expedite traditional research methods. It aims to create a predictive tool that analyzes pathogen genetic sequences and identifies effective vaccine options for rapid outbreak responses. The team is developing this tool using AI-based knowledge extraction, mechanistic modeling, and in vitro and in vivo experiments to test promising candidates. Initially, RAPTER will focus on three pathogens: SARS-CoV-2, Ebola virus, and Burkholderia pseudomallei, the bacterium that causes melioidosis, deemed a significant biological threat.

Overall, the integration of AI and machine learning into vaccine development processes is making this critical field more efficient, scalable, and adaptable to the rapidly evolving landscape of global health threats, ultimately contributing to more effective public health responses. This is expected to contribute to the growth of the vaccines market in the coming years.

Age Group -Based Insights

Based on age group, the vaccines market is segmented into pediatric and adult. The pediatric segment held the largest vaccines market share in 2024. Pediatric vaccines are immunizations given during infancy and childhood to protect against infectious diseases that pose significant risks in early life. These vaccines are typically scheduled in national immunization programs and include protection against diseases such as diphtheria, pertussis, tetanus (DTP), polio, rotavirus, measles, mumps, rubella (MMR), hepatitis B, pneumococcal, and more. This segment continues to grow due to rising awareness about early childhood immunity, increased global coverage efforts by organizations, and strong government mandates in both developed and developing countries. The burden of vaccine-preventable diseases in infants and the long-term health and economic benefits of early immunization have led to sustained policy and funding support. Combination vaccines that reduce the number of injections (e.g., pentavalent or hexavalent) and newer additions like HPV and malaria vaccines for children have further expanded the pediatric portfolio. Advances in vaccine technology, such as thermostable and needle-free delivery systems, also support outreach in low-resource areas, thereby fueling the vaccines market growth.

The World Health Organization and UNICEF are among the primary and secondary sources referred to while preparing the vaccines market report.

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Analyst Market Outlook

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
3.3 Assumptions and Limitations

4. Vaccines Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Vaccines Market - Key Market Dynamics

5.1 Vaccines Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Growing Incidences of Infectious Diseases and Disease Outbreaks
- 5.2.2 Surging Immunization Programs and Government Initiatives
5.3 Market Restraints
- 5.3.1 High Vaccine Development Cost and Increased Time to Market
5.4 Market Opportunities
- 5.4.1 Development of Combination and Therapeutic Vaccines
5.5 Future Trends
- 5.5.1 Integration of Artificial Intelligence and Big Data in Vaccine Development
5.6 Impact of Drivers and Restraints:

6. Vaccines Market - Global Market Analysis

6.1 Vaccines - Global Market Overview
6.2 Vaccines - Global Market and Forecast to 2031

7. Vaccines Market - Revenue Analysis (USD Million) - By Technology, 2020-2031

7.1 Overview
7.2 Live Attenuated Vaccines
- 7.1.1 Overview
- 7.1.2 Live Attenuated Vaccines: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Inactivated Vaccines and Subunit Vaccines
- 7.2.1 Overview
- 7.2.2 Inactivated Vaccines and Subunit Vaccines: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Toxoid Vaccines
- 7.3.1 Overview
- 7.3.2 Toxoid Vaccines: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Conjugate Vaccines
- 7.3.1 Overview
- 7.3.2 Conjugate Vaccines: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Recombinant Vaccines
- 7.3.1 Overview
- 7.3.2 Recombinant Vaccines: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
7.7 Others

8. Vaccines Market - Revenue Analysis (USD Million) - By Disease Indication, 2020-2031

8.1 Overview
8.2 Influenza
- 8.1.1 Overview
- 8.1.2 Influenza: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Dengue
- 8.1.1 Overview
- 8.1.2 Dengue: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Cytomegalovirus (CMV)
- 8.1.1 Overview
- 8.1.2 Cytomegalovirus (CMV): Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Hepatitis
- 8.1.1 Overview
- 8.1.2 Hepatitis: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Respiratory Synical Virus (RSV)
- 8.1.1 Overview
- 8.1.2 Respiratory Synical Virus (RSV): Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
8.7 Other Diseases
- 8.1.1 Overview
- 8.1.2 Other Diseases: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)

9. Vaccines Market - Revenue Analysis (USD Million) - By Route of Administration, 2020-2031

9.1 Overview
9.2 Oral
- 9.1.1 Overview
- 9.1.2 Oral: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Injectable
- 9.1.1 Overview
- 9.1.2 Injectable: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
9.4 Other Route of Administration
- 9.1.1 Overview
- 9.1.2 Other Route of Administration: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)

10. Vaccines Market - Revenue Analysis (USD Million) - By Patient Type, 2020-2031

10.1 Overview
10.2 Pediatric
- 10.2.1 Overview
- 10.2.2 Pediatric: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Adult
- 10.3.1 Overview
- 10.3.2 Adult: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)

11. Vaccines Market - Revenue Analysis (USD Million), 2020-2031 - Geographical Analysis

11.1 North America
- 11.1.1 North America Vaccines Market Overview
- 11.1.2 North America Vaccines Market Revenue and Forecasts to 2031
- 11.1.3 North America Vaccines Market Revenue and Forecasts and Analysis - By Technology
- 11.1.4 North America Vaccines Market Revenue and Forecasts and Analysis - By Disease Indication
- 11.1.5 North America Vaccines Market Revenue and Forecasts and Analysis - By Route of Administration
- 11.1.6 North America Vaccines Market Revenue and Forecasts and Analysis - By Patient Type
- 11.1.7 North America Vaccines Market Revenue and Forecasts and Analysis - By Countries
  - 11.1.7.1 United States Vaccines Market
    - 11.1.7.1.1 United States Vaccines Market, by Technology
    - 11.1.7.1.2 United States Vaccines Market, by Disease Indication
    - 11.1.7.1.3 United States Vaccines Market, by Route of Administration
    - 11.1.7.1.4 United States Vaccines Market, by Patient Type
  - 11.1.7.2 Canada Vaccines Market
    - 11.1.7.2.1 Canada Vaccines Market, by Technology
    - 11.1.7.2.2 Canada Vaccines Market, by Disease Indication
    - 11.1.7.2.3 Canada Vaccines Market, by Route of Administration
    - 11.1.7.2.4 Canada Vaccines Market, by Patient Type
  - 11.1.7.3 Mexico Vaccines Market
    - 11.1.7.3.1 Mexico Vaccines Market, by Technology
    - 11.1.7.3.2 Mexico Vaccines Market, by Disease Indication
    - 11.1.7.3.3 Mexico Vaccines Market, by Route of Administration
    - 11.1.7.3.4 Mexico Vaccines Market, by Patient Type
11.2 Europe
- 10.2.1 Europe Vaccines Market Overview
- 10.2.2 Europe: Vaccines Market - Revenue, 2021-2031 (US$ Million)
  - 10.2.2.1 Europe: Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.2.2.2 Europe: Vaccines Market - Revenue and Forecast Analysis - by Live Attenuated Vaccines
  - 10.2.2.3 Europe: Vaccines Market - Revenue and Forecast Analysis - by Inactivated Vaccines and Subunit Vaccines
  - 10.2.2.4 Europe: Vaccines Market - Revenue and Forecast Analysis - by Disease Indication
  - 10.2.2.5 Europe: Vaccines Market - Revenue and Forecast Analysis - by Influenza
  - 10.2.2.6 Europe: Vaccines Market - Revenue and Forecast Analysis - by Route of Administration
- 10.2.3 Europe: Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.2.3.1 Germany: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.1.1 Germany: Vaccines Market Breakdown, by Technology
    - 10.2.3.1.2 Germany: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.2.3.1.3 Germany: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.2.3.1.4 Germany: Vaccines Market Breakdown, by Disease Indication
    - 10.2.3.1.5 Germany: Vaccines Market Breakdown, by Influenza
    - 10.2.3.1.6 Germany: Vaccines Market Breakdown, by Route of Administration
  - 10.2.3.2 United Kingdom: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.2.1 United Kingdom: Vaccines Market Breakdown, by Technology
    - 10.2.3.2.2 United Kingdom: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.2.3.2.3 United Kingdom: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.2.3.2.4 United Kingdom: Vaccines Market Breakdown, by Disease Indication
    - 10.2.3.2.5 United Kingdom: Vaccines Market Breakdown, by Influenza
    - 10.2.3.2.6 United Kingdom: Vaccines Market Breakdown, by Route of Administration
  - 10.2.3.3 France: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.3.1 France: Vaccines Market Breakdown, by Technology
    - 10.2.3.3.2 France: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.2.3.3.3 France: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.2.3.3.4 France: Vaccines Market Breakdown, by Disease Indication
    - 10.2.3.3.5 France: Vaccines Market Breakdown, by Influenza
    - 10.2.3.3.6 France: Vaccines Market Breakdown, by Route of Administration
  - 10.2.3.4 Italy: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.4.1 Italy: Vaccines Market Breakdown, by Technology
    - 10.2.3.4.2 Italy: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.2.3.4.3 Italy: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.2.3.4.4 Italy: Vaccines Market Breakdown, by Disease Indication
    - 10.2.3.4.5 Italy: Vaccines Market Breakdown, by Influenza
    - 10.2.3.4.6 Italy: Vaccines Market Breakdown, by Route of Administration
  - 10.2.3.5 Spain: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.5.1 Spain: Vaccines Market Breakdown, by Technology
    - 10.2.3.5.2 Spain: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.2.3.5.3 Spain: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.2.3.5.4 Spain: Vaccines Market Breakdown, by Disease Indication
    - 10.2.3.5.5 Spain: Vaccines Market Breakdown, by Influenza
    - 10.2.3.5.6 Spain: Vaccines Market Breakdown, by Route of Administration
  - 10.2.3.6 Rest of Europe: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.6.1 Rest of Europe: Vaccines Market Breakdown, by Technology
    - 10.2.3.6.2 Rest of Europe: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.2.3.6.3 Rest of Europe: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.2.3.6.4 Rest of Europe: Vaccines Market Breakdown, by Disease Indication
    - 10.2.3.6.5 Rest of Europe: Vaccines Market Breakdown, by Influenza
    - 10.2.3.6.6 Rest of Europe: Vaccines Market Breakdown, by Route of Administration
10.3 Asia Pacific
- 10.3.1 Asia Pacific Vaccines Market Overview
- 10.3.2 Asia Pacific: Vaccines Market - Revenue, 2021-2031 (US$ Million)
  - 10.3.2.1 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.3.2.2 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Live Attenuated Vaccines
  - 10.3.2.3 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Inactivated Vaccines and Subunit Vaccines
  - 10.3.2.4 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Disease Indication
  - 10.3.2.5 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Influenza
  - 10.3.2.6 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Route of Administration
- 10.3.3 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.3.3.1 China: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.1.1 China: Vaccines Market Breakdown, by Technology
    - 10.3.3.1.2 China: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.3.3.1.3 China: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.3.3.1.4 China: Vaccines Market Breakdown, by Disease Indication
    - 10.3.3.1.5 China: Vaccines Market Breakdown, by Influenza
    - 10.3.3.1.6 China: Vaccines Market Breakdown, by Route of Administration
  - 10.3.3.2 India: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.2.1 India: Vaccines Market Breakdown, by Technology
    - 10.3.3.2.2 India: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.3.3.2.3 India: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.3.3.2.4 India: Vaccines Market Breakdown, by Disease Indication
    - 10.3.3.2.5 India: Vaccines Market Breakdown, by Influenza
    - 10.3.3.2.6 India: Vaccines Market Breakdown, by Route of Administration
  - 10.3.3.3 Japan: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.3.1 Japan: Vaccines Market Breakdown, by Technology
    - 10.3.3.3.2 Japan: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.3.3.3.3 Japan: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.3.3.3.4 Japan: Vaccines Market Breakdown, by Disease Indication
    - 10.3.3.3.5 Japan: Vaccines Market Breakdown, by Influenza
    - 10.3.3.3.6 Japan: Vaccines Market Breakdown, by Route of Administration
  - 10.3.3.4 Australia: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.4.1 Australia: Vaccines Market Breakdown, by Technology
    - 10.3.3.4.2 Australia: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.3.3.4.3 Australia: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.3.3.4.4 Australia: Vaccines Market Breakdown, by Disease Indication
    - 10.3.3.4.5 Australia: Vaccines Market Breakdown, by Influenza
    - 10.3.3.4.6 Australia: Vaccines Market Breakdown, by Route of Administration
  - 10.3.3.5 South Korea: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.5.1 South Korea: Vaccines Market Breakdown, by Technology
    - 10.3.3.5.2 South Korea: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.3.3.5.3 South Korea: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.3.3.5.4 South Korea: Vaccines Market Breakdown, by Disease Indication
    - 10.3.3.5.5 South Korea: Vaccines Market Breakdown, by Influenza
    - 10.3.3.5.6 South Korea: Vaccines Market Breakdown, by Route of Administration
  - 10.3.3.6 Rest of APAC: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.6.1 Rest of APAC: Vaccines Market Breakdown, by Technology
    - 10.3.3.6.2 Rest of APAC: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.3.3.6.3 Rest of APAC: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.3.3.6.4 Rest of APAC: Vaccines Market Breakdown, by Disease Indication
    - 10.3.3.6.5 Rest of APAC: Vaccines Market Breakdown, by Influenza
    - 10.3.3.6.6 Rest of APAC: Vaccines Market Breakdown, by Route of Administration
10.4 Middle East and Africa
- 10.4.1 Middle East and Africa Vaccines Market Overview
- 10.4.2 Middle East and Africa: Vaccines Market - Revenue, 2021-2031 (US$ Million)
  - 10.4.2.1 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.4.2.2 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Live Attenuated Vaccines
  - 10.4.2.3 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Inactivated Vaccines and Subunit Vaccines
  - 10.4.2.4 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Disease Indication
  - 10.4.2.5 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Influenza
  - 10.4.2.6 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Route of Administration
- 10.4.3 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.4.3.1 South Africa: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.3.1.1 South Africa: Vaccines Market Breakdown, by Technology
    - 10.4.3.1.2 South Africa: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.4.3.1.3 South Africa: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.4.3.1.4 South Africa: Vaccines Market Breakdown, by Disease Indication
    - 10.4.3.1.5 South Africa: Vaccines Market Breakdown, by Influenza
    - 10.4.3.1.6 South Africa: Vaccines Market Breakdown, by Route of Administration
  - 10.4.3.2 Saudi Arabia: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.3.2.1 Saudi Arabia: Vaccines Market Breakdown, by Technology
    - 10.4.3.2.2 Saudi Arabia: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.4.3.2.3 Saudi Arabia: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.4.3.2.4 Saudi Arabia: Vaccines Market Breakdown, by Disease Indication
    - 10.4.3.2.5 Saudi Arabia: Vaccines Market Breakdown, by Influenza
    - 10.4.3.2.6 Saudi Arabia: Vaccines Market Breakdown, by Route of Administration
  - 10.4.3.3 United Arab Emirates: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.3.3.1 United Arab Emirates: Vaccines Market Breakdown, by Technology
    - 10.4.3.3.2 United Arab Emirates: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.4.3.3.3 United Arab Emirates: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.4.3.3.4 United Arab Emirates: Vaccines Market Breakdown, by Disease Indication
    - 10.4.3.3.5 United Arab Emirates: Vaccines Market Breakdown, by Influenza
    - 10.4.3.3.6 United Arab Emirates: Vaccines Market Breakdown, by Route of Administration
  - 10.4.3.4 Rest of Middle East and Africa: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.3.4.1 Rest of Middle East and Africa: Vaccines Market Breakdown, by Technology
    - 10.4.3.4.2 Rest of Middle East and Africa: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.4.3.4.3 Rest of Middle East and Africa: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.4.3.4.4 Rest of Middle East and Africa: Vaccines Market Breakdown, by Disease Indication
    - 10.4.3.4.5 Rest of Middle East and Africa: Vaccines Market Breakdown, by Influenza
    - 10.4.3.4.6 Rest of Middle East and Africa: Vaccines Market Breakdown, by Route of Administration
10.5 South and Central America
- 10.5.1 South and Central America Vaccines Market Overview
- 10.5.2 South and Central America: Vaccines Market - Revenue, 2021-2031 (US$ Million)
  - 10.5.2.1 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.5.2.2 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Live Attenuated Vaccines
  - 10.5.2.3 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Inactivated Vaccines and Subunit Vaccines
  - 10.5.2.4 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Disease Indication
  - 10.5.2.5 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Influenza
  - 10.5.2.6 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Route of Administration
- 10.5.3 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.5.3.1 Brazil: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.3.1.1 Brazil: Vaccines Market Breakdown, by Technology
    - 10.5.3.1.2 Brazil: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.5.3.1.3 Brazil: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.5.3.1.4 Brazil: Vaccines Market Breakdown, by Disease Indication
    - 10.5.3.1.5 Brazil: Vaccines Market Breakdown, by Influenza
    - 10.5.3.1.6 Brazil: Vaccines Market Breakdown, by Route of Administration
  - 10.5.3.2 Argentina: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.3.2.1 Argentina: Vaccines Market Breakdown, by Technology
    - 10.5.3.2.2 Argentina: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.5.3.2.3 Argentina: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.5.3.2.4 Argentina: Vaccines Market Breakdown, by Disease Indication
    - 10.5.3.2.5 Argentina: Vaccines Market Breakdown, by Influenza
    - 10.5.3.2.6 Argentina: Vaccines Market Breakdown, by Route of Administration
  - 10.5.3.3 Rest of South and Central America: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.3.3.1 Rest of South and Central America: Vaccines Market Breakdown, by Technology
    - 10.5.3.3.2 Rest of South and Central America: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.5.3.3.3 Rest of South and Central America: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.5.3.3.4 Rest of South and Central America: Vaccines Market Breakdown, by Disease Indication
    - 10.5.3.3.5 Rest of South and Central America: Vaccines Market Breakdown, by Influenza
    - 10.5.3.3.6 Rest of South and Central America: Vaccines Market Breakdown, by Route of Administration

12. Industry Landscape

12.1 Mergers and Acquisitions
12.2 Agreements, Collaborations, Joint Ventures
12.3 New Product Launches
12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

13.1 Heat Map Analysis by Key Players
13.2 Ranking by Key Players

14. Vaccines Market - Key Company Profiles

14.1 GlaxoSmithKline plc
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Pfizer Inc.
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Sanofi
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Merck and Co., Inc
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Serum Institute of India (SII)
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 BioNTech
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Abbott
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Sinovac
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Novartis
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 CSL Seqirus
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments

15. Appendix

15.1 Glossary
15.2 About The Insight Partners
15.3 Market Intelligence Cloud